Name | IAXO-102 |
Synonyms | IAXO-102 Methyl 6-amino-6-deoxy-2,3-di-O-tetradecyl-α-D-glucopyranoside α-D-Glucopyranoside, methyl 6-amino-6-deoxy-2,3-di-O-tetradecyl- |
CAS | 1115270-63-7 |
Molecular Formula | C35H71NO5 |
Molar Mass | 585.96 |
Density | 0.96±0.1 g/cm3(Predicted) |
Boling Point | 650.2±55.0 °C(Predicted) |
pKa | 13.00±0.70(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
Use | IAXO-102 is a TLR4 antagonist which negatively regulates TLR4 signalling. It inhibits MAPK and p65 N |
In vitro study | IAXO-102 (1-10 µM, for 2 hours) inhibits MAPK and p65 NF-κB phosphorylation in human umbilical vein endothelial (HUVEC) cells. IAXO-102 (10 µM, for 17 hours) suppresses LPS induced proinflammatory proteins MCP-1 and IL-8 production in HUVEC. Western Blot Analysis Cell Line: Human umbilical vein endothelial (HUVEC) cells Concentration: 1-10 µM Incubation Time: Pretreatment for 1 hour and then exposed to LPS (100 ng/mL) for additional 1 hour Result: Significantly inhibited LPS-stimulated MAPK/p65nF-ΚB phosphorylation. |
In vivo study | IAXO-102 (3 mg/kg/day, s.c. for 28 days) significantly retards Angiotensin II induced increase in aortic diameter in mice. Animal Model: Six-monthold ApoE −/− /C57Bl6 Dosage: 3 mg/kg/day Administration: S.C. for 28 days Result: Significantly retarded Angiotensin II-induced increase in aortic diameter. |